 |
Institute of Metabolic Disease at Baylor Research Institute
 |
Lipo-Protein (a)
Lp(a) consists of two components, the low-density lipoprotein (LDL) and a glycoprotein, the apolipoprotein(a) [Apo(a)], which are linked by a disulfide bridge. Numerous epidemiological studies have shown that elevated concentrations of Lp(a) is a risk factor for coronary heart disease and stroke. Most in vitro functions that have been attributed to Lp(a) have also been suggested as an explanation for the pathophysiological properties of Lp(a) and may be responsible for the fatal consequences of excessive Lp(a) levels in human subjects. One is the modulation of the balance between clotting and fibrinolysis at the endothelial cell layer of the blood vessel wall, which results in a prothrombotic state. In vitro studies also suggest that a forming fibrin thrombus at a damaged vessel wall has the capacity to bind Lp(a). This may not only inhibit thrombus degradation but may also result in the trapping of the Lp(a) particle by cross-linking with fibrinogen. High homocysteine concentrations enhance
fibrin binding of Lp(a) and might accelerate thrombus formation.
Department: Neuropharmacology
Methodology: Nephalometric detection
Sample:
Plasma – 0.5 mL of heparinized plasma.
Serum – 0.5 mL
Shipping/Handling:
For both sample types, spin down the sample within 1 hour of collection. Freeze sample and ship overnight on 3-4 lbs of dry ice.
Special Notes: This research test must be coordinated through the Neuropharmacology Laboratory Director. Most research tests are performed on a batch basis; the laboratory will not perform single sample testing. Contact the Neuropharmacology Laboratory Director for more information.
Turnaround Time and Test Cost: Contact the Neuropharmacology Laboratory Director.
Related tests: Apolipoprotein A1, Apolipoprotein B, hs-C Reative Protein, Homocysteine (total) |
|
Baylor Intranet |
Baylor Portal